IRS2 and metabolic dysfunction-associated steatotic liver disease: BBR can improve insulin resistance (Yan et al., 2015) by upregulating insulin receptor substrate-2 (IRS-2) (Xing et al., 2011) and down regulating UCP2 at the mRNA and protein levels along with a decrease in TC, TG, and LDL-C and an increase in HDL-C in HFD-induced NAFLD model rats (Zhao et al., 2017).